Recce Pharmaceuticals' RECCE 327 Added to WHO's List of Antibacterial Products in Clinical Development

Recce Pharmaceuticals (ASX:RCE) said its anti-infective agent, RECCE 327, was added to the World Health Organization's list of antibacterial products in clinical development. The addition highlights R

MT NewswiresJun 18 10:24

Recce Pharmaceuticals Completes Dosing in Urosepsis Rapid Infusion Clinical Trial

Recce Pharmaceuticals (ASX:RCE) completed dosing of its latest cohort comprising six human subjects in its phase I/II clinical trial for UTI/Urosepsis treatment, according to a Tuesday filing with the

MT NewswiresJun 11 09:56

Recce Pharmaceuticals Doses First Patient in Urosepsis Rapid Infusion Clinical Trial

Recce Pharmaceuticals (ASX:RCE) administered RECCE 327 to the first male and female participants in the following cohort, with a dosage of 4,000mg intravenously, delivered at a rapid infusion rate of

MT NewswiresMay 15 15:38

Recce Pharma Heading Closer to Full Efficacy Data for Flagship R327

Recce Pharma (ASX:RCE) has announced the latest cohort of patients part of the company’s Phase I/II UTI trial has been dosed with the highest ever volume of R327 to date.

The Market HeraldMay 15 10:20

Recce Pharmaceuticals Finds 'Promising' Results From Nebulized RECCE 327 Pilot Study

Recce Pharmaceuticals (ASX:RCE) reported "promising" results from its latest pilot study on the efficacy of nebulized RECCE 327 for treating lung infections in a mouse model, further highlighting its

MT NewswiresMay 10 13:02

Recce Breathes Better on Positive Lung Infection Drug Pilot Test Results

A pilot study testing the effectiveness of a synthetic drug to treat lung infections has yielded positive data for Australian-based Recce Pharmaceuticals Ltd (ASX:RCE).

The Market HeraldMay 9 11:59